|
Kathleen Francissen
Global Head, Cell & Gene Therapy Regulatory
Roche-Genentech
South San Francisco, CA
USA
|
Dr. Francissen serves as the Rapporteur of the ICH Cell and Gene Therapy Discussion Group (ICH CGT DG), representing BIO. She has been dedicated to the development of ATMPs for the past several years, thus leveraging >25 years of experience in biopharmaceutical development. She leads a team of regulatory professionals responsible for developing and implementing regulatory strategies for ATMP programs in the Roche-Genentech portfolio. In addition, she is the chair of the Casss 2024 Cell & Gene Therapy Products (CGTP) Symposium.